Clinical Trial

Phase I Study of HRS-3005 in B-cell Malignancies

Name: Phase I Study of HRS-3005 in B-cell Malignancies — clinical trial record (NCT07556822)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The study is being conducted to evaluate the safety and tolerability of HRS-3005. To explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-3005 in patients with B-cell malignancy.

Protocol Amendment History 1 change

critical Recruitment opened 2026-06-11

Trial Details

NCT Number	NCT07556822
Lead Sponsor	Jiangsu HengRui Medicine Co., Ltd.
Conditions	B-cell Malignancy
Enrollment	190 participants
Start Date	2026-06-03
Primary Completion	2028-10 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-10